Dataset Information

Asian Society of Gynecologic Oncology International Workshop 2018.

ABSTRACT: The Asian Society of Gynecologic Oncology International Workshop 2018 on gynecologic oncology was held in the Ajou University Hospital, Suwon, Korea on the 24th to 25th August 2018. The workshop was an opportunity for Asian doctors to discuss the latest findings of gynecologic cancer, including cervical, ovarian, and endometrial cancers, as well as the future of fertility-sparing treatments, minimally invasive/radical/debulking surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Clinical guidelines and position statement of Asian countries were presented by experts. Asian clinical trials for gynecologic cancers were reviewed and experts emphasized the point that original Asian study is beneficial for Asian patients. In Junior session, young gynecologic oncologists presented their latest research on gynecologic cancers.

SUBMITTER: Kong TW

PROVIDER: S-EPMC6393643 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Asian Society of Gynecologic Oncology International Workshop 2018.

Kong Tae Wook TW Ryu Hee Sug HS Kim Seung Cheol SC Enomoto Takayuki T Li Jin J Kim Kenneth H KH Shim Seung Hyuk SH Wang Peng Hui PH Therasakvichya Suwanit S Kobayashi Yusuke Y Lee Maria M Shi Tingyan T Lee Shin Wha SW Mikami Mikio M Nagase Satoru S Nagase Satoru S Lim Myong Cheol MC Wang Jianliu J Wilailak Sarikapan S Kim Sang Wun SW Hong Sook Hee SH Tan David Sp DS Mandai Masaki M Chang Suk Joon SJ Huang Ruby Yun Ju RYJ Ushijima Kimio K Lee Jung Yun JY Chen Xiaojun X Ochiai Kazunori K Lee Taek Sang TS Yang Bingyi B Kalam Farhana F Lv Qiaoying Q Ahmad Mohd Faizal MF Yaznil Muhammad Rizki MR Modi Kanika Batra KB Manopunya Manatsawee M Jeong Dae Hoon DH Lertkhachonsuk Arb Aroon AA Chung Hyun Hoon HH Watari Hidemichi H Jeon Seob S

Journal of gynecologic oncology 20190114 2

The Asian Society of Gynecologic Oncology International Workshop 2018 on gynecologic oncology was held in the Ajou University Hospital, Suwon, Korea on the 24th to 25th August 2018. The workshop was an opportunity for Asian doctors to discuss the latest findings of gynecologic cancer, including cervical, ovarian, and endometrial cancers, as well as the future of fertility-sparing treatments, minimally invasive/radical/debulking surgery, radiotherapy, chemotherapy, targeted therapy, and immunothe ...[more]

PMID: 30740961

Similar Datasets

Project description:To explore the value of multiple clinical endpoints in the unique setting of ovarian cancer.A clinical trial workgroup was established by the Society of Gynecologic Oncology to develop a consensus statement via multiple conference calls, meetings and white paper drafts.Clinical trial endpoints have profound effects on late phase clinical trial design, result interpretation, drug development, and regulatory approval of therapeutics. Selection of the optimal clinical trial endpoint is particularly provocative in ovarian cancer where long overall survival (OS) is observed. The lack of new regulatory approvals and the lack of harmony between regulatory bodies globally for ovarian cancer therapeutics are of concern. The advantages and disadvantages of the numerous endpoints available are herein discussed within the unique context of ovarian cancer where both crossover and post-progression therapies potentially uncouple surrogacy between progression-free survival (PFS) and OS, the two most widely supported and utilized endpoints. The roles of patient reported outcomes (PRO) and health related quality of life (HRQoL) are discussed, but even these widely supported parameters are affected by the unique characteristics of ovarian cancer where a significant percentage of patients may be asymptomatic. Original data regarding the endpoint preferences of ovarian cancer advocates is presented.Endpoint selection in ovarian cancer clinical trials should reflect the impact on disease burden and unique characteristics of the treatment cohort while reflecting true patient benefit. Both OS and PFS have led to regulatory approvals and are clinically important. OS remains the most objective and accepted endpoint because it is least vulnerable to bias; however, the feasibility of OS in ovarian cancer is compromised by the requirement for large trial size, prolonged time-line for final analysis, and potential for unintended loss of treatment effect from active post-progression therapies. A large magnitude of effect in PFS improvement should establish benefit, and further communication with regulatory authorities to clarify acceptable endpoints should be undertaken.

Dataset Information

Asian Society of Gynecologic Oncology International Workshop 2018.

Publications

Asian Society of Gynecologic Oncology International Workshop 2018.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets